These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2516529)

  • 1. The prevention of biochemical changes in lens, retina, and nerve of galactosemic dogs by the aldose reductase inhibitor AL01576.
    Lou MF; Dickerson JE; Chandler ML; Brazzell RK; York BM
    J Ocul Pharmacol; 1989; 5(3):233-40. PubMed ID: 2516529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D; Mirrlees DJ; Harrison HE; Earl DC
    Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
    Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
    Metabolism; 1979 Apr; 28(4 Suppl 1):456-61. PubMed ID: 122297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of polyol pathway activity in diabetic and galactosemic rats by the aldose reductase inhibitor CP-45,634.
    Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
    Adv Exp Med Biol; 1979; 119():347-56. PubMed ID: 115231
    [No Abstract]   [Full Text] [Related]  

  • 5. Glutathione depletion in the lens of galactosemic and diabetic rats.
    Lou MF; Dickerson JE; Garadi R; York BM
    Exp Eye Res; 1988 Apr; 46(4):517-30. PubMed ID: 3133235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor.
    Kern TS; Engerman RL
    Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3175-7. PubMed ID: 1748548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of naphthalene cataract in rats by aldose reductase inhibitors.
    Lou MF; Xu GT; Zigler S; York B
    Curr Eye Res; 1996 Apr; 15(4):423-32. PubMed ID: 8670742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of lens protein kinase Cgamma in galactosemic dogs by a novel aldose reductase inhibitor.
    Takemoto DJ; Harris R; Brightman A; McGill J; Hua D; Davidson H; Fenwick B; Wagner LM
    Vet Ophthalmol; 2004; 7(3):163-7. PubMed ID: 15091323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
    Malamas MS; Hohman TC; Millen J
    J Med Chem; 1994 Jun; 37(13):2043-58. PubMed ID: 8027986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of AL01576 concentration in rat lenses and plasma by bioassay for aldose reductase activity measurements.
    Hockwin O; Müller P; Krolczyk J; McCue BA; Mayer PR
    Ophthalmic Res; 1989; 21(4):285-91. PubMed ID: 2511536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.
    Simard-Duquesne N; Greselin E; Dubuc J; Dvornik D
    Metabolism; 1985 Oct; 34(10):885-92. PubMed ID: 3930915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of aldose reductase in sugar cataract formation: aldose reductase plays a key role in lens epithelial cell death (apoptosis).
    Murata M; Ohta N; Sakurai S; Alam S; Tsai J; Kador PF; Sato S
    Chem Biol Interact; 2001 Jan; 130-132(1-3):617-25. PubMed ID: 11306080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
    Yue DK; Hanwell MA; Satchell PM; Handelsman DJ; Turtle JR
    Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor.
    Obrosova I; Faller A; Burgan J; Ostrow E; Williamson JR
    Curr Eye Res; 1997 Jan; 16(1):34-43. PubMed ID: 9043821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
    Frank RN; Amin R; Kennedy A; Hohman TC
    Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
    Griffin BW; McNatt LG; Chandler ML; York BM
    Metabolism; 1987 May; 36(5):486-90. PubMed ID: 3106757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of SG-210, a novel aldose reductase inhibitor, on impaired polyol pathway in rats received diabetic manipulations.
    Horie S; Nagai H; Yuuki T; Narita Y; Tsuda Y; Nakajima T; Nakamura N
    J Diabetes Complications; 1998; 12(3):163-9. PubMed ID: 9618072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aldose reductase inhibitors on lenticular dulcitol level in galactose fed rats.
    Unakar NJ; Tsui JY; Johnson MJ
    J Ocul Pharmacol; 1992; 8(3):199-212. PubMed ID: 1453083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of potent aldose reductase inhibitors having a hydantoin structure.
    Miwa I; Hirano M; Inagaki K; Belbeoc'h C; Okuda J
    Biochem Pharmacol; 1987 Sep; 36(17):2789-94. PubMed ID: 3115267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AL-1576, an aldose reductase inhibitor (ARI), did not prevent the decrease of norepinephrine turnover in diabetic rats.
    Yen TT; Fuller RW; Broderick CL; Hemrick-Luecke SK; Perry KW
    Res Commun Chem Pathol Pharmacol; 1988 Aug; 61(2):257-60. PubMed ID: 3141993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.